StemVacs-A is under clinical development by Therapeutic Solutions International and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how StemVacs-A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
StemVacs-A overview
Therapeutic Solutions International overview
Therapeutic Solutions International (Therapeutic Solutions) is a pharmaceutical company that developed immune modulation for the treatment of several specific diseases. The company product pipeline includes ARDScells Phase 3, JadiCell ARDS Phase 3, CTEcells Phase 1/2, StemVacs-A Phase 1, StemVacs-V Phase 1/2, ALScells, StemVacs-E, StemVacs-P, StemVacs-L, JadiCell_DC_Exosomes, JadiCell Lithium, JadiCell Schizophrenia, LymphoBoost, JadiCell Neurogenesis, NarcoStem. The therapeutic Solutions pipeline also includes NeuroLeukin, CampbellCell, siRNA ARDS, RNA/CTE and VSX-001. Therapeutic Solutions is headquartered in Oceanside, California?, the US.
For a complete picture of StemVacs-A’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
